Works matching IS 25739832 AND DT 2019 AND VI 1 AND IP 2
Results: 6
Issue Information.
- Published in:
- FASEB Bioadvances, 2019, v. 1, n. 2, p. 63, doi. 10.1096/fba.1040
- Publication type:
- Article
Drysdalin, an antagonist of nicotinic acetylcholine receptors highlights the importance of functional rather than structural conservation of amino acid residues.
- Published in:
- FASEB Bioadvances, 2019, v. 1, n. 2, p. 115, doi. 10.1096/fba.1027
- By:
- Publication type:
- Article
Tumor gene therapy by systemic delivery of plasmid DNA with cell‐penetrating peptides.
- Published in:
- FASEB Bioadvances, 2019, v. 1, n. 2, p. 105, doi. 10.1096/fba.1026
- By:
- Publication type:
- Article
New technologies to introduce a catalytic function into antibodies: A unique human catalytic antibody light chain showing degradation of β‐amyloid molecule along with the peptidase activity.
- Published in:
- FASEB Bioadvances, 2019, v. 1, n. 2, p. 93, doi. 10.1096/fba.1025
- By:
- Publication type:
- Article
Intramuscular administration of hexachloroplatinate reverses cyanide‐induced metabolic derangements and counteracts severe cyanide poisoning.
- Published in:
- FASEB Bioadvances, 2019, v. 1, n. 2, p. 81, doi. 10.1096/fba.1024
- By:
- Publication type:
- Article
High‐level expression of STING restricts susceptibility to HBV by mediating type III IFN induction.
- Published in:
- FASEB Bioadvances, 2019, v. 1, n. 2, p. 67, doi. 10.1096/fba.1022
- By:
- Publication type:
- Article